Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A panel of autologous cytolytic T lymphocyte (CTL) clones have been isolated from blood lymphocytes of a melanoma patient after in vitro stimulation with autologous tumor cells. We previously reported the molecular definition of three distinct antigens recognized by some of these CTL clones. We describe here, the identification of a fourth antigenic peptide expressed by this melanoma line and recognized by a CTL clone restricted by HLA-B*3503. The antigenic peptide, which is nine-amino acid long, has the sequence LPHSSSHWL and is derived from melanocyte differentiation antigen gp100. As HLA-B35 is one of the most frequent HLA-B alleles, being present in 20% of the Caucasian individuals, this peptide may be a good target for peptide-based immunotherapy of melanoma.

Original publication




Journal article


Tissue Antigens

Publication Date





156 - 162


Amino Acid Sequence, Animals, COS Cells, Cercopithecus aethiops, Cytotoxicity, Immunologic, HLA-B35 Antigen, Humans, Melanocytes, Melanoma, Membrane Glycoproteins, Molecular Sequence Data, Neoplasm Proteins, Peptide Fragments, Skin Neoplasms, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, gp100 Melanoma Antigen